“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

BACKGROUND: The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising outcomes, there were limited apheresis/production slots for ide-cel. We report outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Nausheen, Wesson, William, Mushtaq, Muhammad Umair, Bansal, Rajat, AbdelHakim, Haitham, Bromert, Sarah, Appenfeller, Allison, Ghazal, Batool Abu, Singh, Anurag, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph, Abdallah, Al-Ola, Shune, Leyla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436079/
https://www.ncbi.nlm.nih.gov/pubmed/37601685
http://dx.doi.org/10.3389/fonc.2023.1206715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436079/
https://www.ncbi.nlm.nih.gov/pubmed/37601685
http://dx.doi.org/10.3389/fonc.2023.1206715

Ejemplares similares